Merck Ventures creates new immuno-oncology company iOnctura

Merck, a leading science and technology company, today announced its corporate venture arm Merck Ventures created iOnctura SA, Geneva, Switzerland. This immuno-oncology spin-out company was formed around two assets from the Healthcare R&D portfolio of Merck and three assets from Cancer Research Technology (CRT).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news